Article Information
History
- October 2, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Mathilde Saint-Ghislain1,11,
- Sylvie Chabaud2,
- Florence Dalenc3,
- Djelila Allouache4,
- David Cameron5,
- Mathilde Martinez6,
- Julien Grenier7,
- Philippe Barthelemy8,
- Murray Brunt9,
- Laure Kaluzinski10,
- Audrey Mailliez11,
- Eric Legouffe12,
- Anne-Claire Hardy-Bessard13,
- Sylvie Giacchetti14,
- Marie-Ange Mouret-Reynier15,
- Jean-Luc Canon16,
- Judith Bliss17,
- Jérôme Lemonnier18,
- Fabrice Andre19,
- Thomas Bachelot2 and
- Paul Cottu1,20,*
- 1Institut Curie, Paris, France
- 2Centre Léon Bérard, Lyon, France
- 3Institut Universitaire de Cancérologie de Toulouse – Institut Claudius Régaud, Toulouse, France
- 4Centre François Baclesse, Caen, France
- 5Western General Hospital, Edinburg, United Kingdom
- 6Clinique Pasteur, Toulouse, France
- 7Institut Sainte Catherine, Avignon, France
- 8Institut de Cancérologie Strasbourg Europe, Strasbourg, France
- 9Royal Stoke Hospital, Stoke-on-Trent, United Kingdom
- 10Centre Hospitalier du Cotentin, Cherbourg en Cotentin, France
- 11Centre Oscar Lambret, Lille, France
- 12Centre Oncogard, Nîmes, France
- 13Centre CARIO -HPCA, Plérin, France
- 14Hôpital Saint Louis, Paris, France
- 15Centre Jean Perrin, Clermont-Ferrand, France
- 16Grand Hôpital de Charleroi, Charleroi, Belgium
- 17The Institute of Cancer Research, London, United Kingdom
- 18UNICANCER, Paris, France
- 19Gustave Roussy, Villejuif, France
- 20Université Paris-Cité, Paris, France
- ↵*Corresponding Author Paul Cottu, MD, PhD Department of Medical Oncology Institut Curie 26 rue d’Ulm 75005 Paris France T: +3317238943 Email: paul.cottu{at}curie.fr
Posted October 02, 2024.
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial
